[68Ga]Ga-LNTH-1363S(靶向成纤维细胞激活蛋白α的探针)在癌症患者中的生物分布与辐射剂量学
本研究在5例肿瘤患者(乳腺癌、甲状腺乳头状癌)中评估靶向成纤维细胞激活蛋白(FAP)的示踪剂[68Ga]Ga-LNTH-1363S的PET生物分布与辐射剂量学。静脉注射153-184 MBq后于10、60、180分钟行PET/CT,按MIRD形式进行正常组织剂量学并分析SUV。结果显示肿瘤快速摄取、非靶组织清除迅速,各时间点肿瘤/本底比值高;肾脏吸收剂量最高(0.038 ± 0.01 mGy/MBq),有效剂量(0.013 ± 0.002 mSv/MBq)与其他FAP示踪剂一致,随访期间未观察到不良事件。
要点
- 5例肿瘤患者注射153-184 MBq [68Ga]Ga-LNTH-1363S后于10、60、180分钟行PET/CT。
- 肿瘤SUVmax在注射后10分钟达峰值(18.6 ± 7.2),后续时间点仍保持较高。
- 正常组织中肾脏吸收剂量最高(0.038 ± 0.01 mGy/MBq),有效剂量为0.013 ± 0.002 mSv/MBq。
核心结论
- [68Ga]Ga-LNTH-1363S具有有利的剂量学和生物分布特征,与其他FAP靶向示踪剂相当。
研究设计与样本
- 研究纳入5例肿瘤患者(乳腺癌、甲状腺乳头状癌),静脉注射153-184 MBq [68Ga]Ga-LNTH-1363S。
- 注射后10、60、180分钟行PET/CT显像,按MIRD剂量学形式进行正常组织剂量学评估,并分析正常组织与肿瘤的SUV。
主要发现
- [68Ga]Ga-LNTH-1363S生物分布显示肿瘤快速摄取、非靶组织清除迅速,各显像时间点肿瘤/本底比值高。
- 正常组织中肾脏吸收剂量最高(0.038 ± 0.01 mGy/MBq),其次为胰腺和唾液腺。
- 肿瘤SUVmax在注射后10分钟达峰值(18.6 ± 7.2),后续时间点仍保持较高。
- 随访期间未观察到不良事件,有效剂量(0.013 ± 0.002 mSv/MBq)与其他FAP示踪剂一致。
关键数值与推荐
- 正常组织中肾脏吸收剂量最高,为0.038 ± 0.01 mGy/MBq。
- 肿瘤SUVmax在注射后10分钟达峰值,为18.6 ± 7.2。
- 有效剂量为0.013 ± 0.002 mSv/MBq。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study is to evaluate the PET biodistribution and radiation dosimetry of the fibroblast activation protein (FAP)-targeted tracer [68Ga]Ga-LNTH-1363S in cancer patients. Methods: Five patients with oncologic diseases (breast cancer, papillary thyroid carcinoma) were injected intravenously with 153-184 MBq of [68Ga]Ga-LNTH-1363S. PET/CT imaging was performed at 10, 60, and 180 min after administration of [68Ga]Ga-LNTH-1363S. Normal tissue dosimetry was performed following the MIRD dosimetry formalism. SUV analysis of normal tissues and tumors was performed. Results: The biodistribution of [68Ga]Ga-LNTH-1363S demonstrated rapid tumor uptake and efficient clearance from nontarget tissues, resulting in high tumor-to-background ratios at all imaging time points. The kidneys received the highest absorbed dose among normal tissues (0.038 ± 0.01 mGy/MBq), followed by the pancreas and salivary glands. The tumor SUVmax peaked at 10 min after injection (18.6 ± 7.2) and remained high at later time points. No adverse events were observed during follow-up, and the effective dose (0.013 ± 0.002 mSv/MBq) was consistent with other FAP tracers. Conclusion: [68Ga]Ga-LNTH-1363S offers favorable dosimetry and biodistribution profiles, comparable with other FAP-targeted tracers.
引用
- Enke JS, Schuller BW, Glantschnig L, et al. Biodistribution and Radiation Dosimetry for [68Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein α. J Nucl Med. 2025. PMID: 40533357. doi:10.2967/jnumed.125.269793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。